Opportunity Information: Apply for PAR 13 061
Apply for PAR 13 061
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Research in latent tuberculosis infection (LTBI) in the setting of HIV Co Infection (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Dec 20, 2012 and posted on Dec 20, 2012.
- Applicants must submit their applications by Jul 24, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments State governments Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Special district governments Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Independent school districts Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity, PAR 13-061, is an NIH National Institute of Allergy and Infectious Diseases (NIAID) R01 research grant focused on latent tuberculosis infection (LTBI) in the specific context of HIV co-infection. The central goal is to support studies that deepen understanding of how Mycobacterium tuberculosis persists in a latent state, what biological and immunologic conditions allow latency to be established and maintained, and what mechanisms lead to reactivation into active tuberculosis, with particular emphasis on how HIV alters these processes. In practical terms, the announcement is seeking projects that can clarify the microbial survival strategies used during latency, the host immune factors that normally contain infection, and the combined host-pathogen interactions that determine whether LTBI remains controlled or progresses to active disease when HIV is present.
The scientific scope highlights three tightly connected themes: microbiologic adaptive mechanisms (how the bacterium adjusts to immune pressure and a low-nutrient, low-oxygen, or otherwise constrained environment), host immunologic factors (the immune cell types, signaling pathways, inflammatory environments, and protective responses that contain TB), and the interaction between the two (how bacterial adaptations shape immune responses and how HIV-driven immune dysfunction changes bacterial behavior and disease trajectory). By emphasizing HIV co-infection, the opportunity is aligned with a major public health issue: people living with HIV have a substantially higher risk of progressing from latent TB to active TB, and the biological reasons for that elevated risk are complex and not fully understood. Applications responsive to this opportunity would typically aim to identify mechanisms, markers, or pathways that explain why latency fails more often in HIV, potentially informing better preventive strategies, diagnostics, vaccines, or host-directed therapies.
Administratively, this is a discretionary grant opportunity using the NIH R01 funding instrument, intended for health-related research within the NIH allergy, immunology, microbiology, and infectious diseases mission space. It is associated with CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). The opportunity was posted and created on December 20, 2012, with an original and final closing date of July 24, 2015, and it was archived on August 24, 2015. No cost sharing or matching is required, meaning applicants are not expected to provide non-federal matching funds as a condition of award.
Eligibility is broad and includes a wide range of domestic and international organizations capable of conducting the proposed research. Eligible applicants include public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status, other than institutions of higher education), for-profit organizations (other than small businesses), small businesses, and multiple levels of government such as city/township, county, and state governments, as well as special district governments and independent school districts. The announcement also explicitly includes tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and a wide set of mission-relevant institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander-Serving Institutions (AANAPISI). Faith-based and community-based organizations and eligible federal agencies may apply as well.
International participation is permitted in several forms. Non-U.S. entities (foreign organizations and foreign institutions) are eligible to apply, and non-U.S. components of U.S. organizations may participate. Foreign components, as defined by the NIH Grants Policy Statement, are also allowed, which typically enables projects to include overseas performance sites, collaborations, cohorts, or laboratory components when scientifically justified. This matters for TB and HIV research because key patient populations and transmission settings are often outside the United States, and the ability to build studies in high-burden settings can be essential to answering latency and reactivation questions.
For applicants or institutions seeking the official announcement text, the NIH provides an additional information link to the full Funding Opportunity Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-13-061.html. For technical issues accessing or linking to the announcement, the listed contact is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs): PAR-13-061 (NIAID R01) - Latent Tuberculosis Infection in the Context of HIV
1) What is PAR-13-061?
PAR-13-061 is an NIH Funding Opportunity Announcement from the National Institute of Allergy and Infectious Diseases (NIAID) that uses the R01 research project grant mechanism to support research on latent tuberculosis infection (LTBI), specifically focusing on how HIV co-infection affects latency and reactivation.
2) Which NIH institute is associated with this opportunity?
This opportunity is associated with the NIH National Institute of Allergy and Infectious Diseases (NIAID).
3) What grant mechanism (funding instrument) does this announcement use?
The funding instrument is the NIH R01 research grant (Research Project Grant).
4) What is the overall purpose of this funding opportunity?
The purpose is to support studies that deepen understanding of how Mycobacterium tuberculosis persists in a latent state, what biological and immunologic conditions allow latency to be established and maintained, and what mechanisms lead to reactivation into active tuberculosis, with particular emphasis on how HIV alters these processes.
5) What scientific areas are emphasized in the scope?
The scope highlights three connected themes: (1) microbiologic adaptive mechanisms used during latency, (2) host immunologic factors that contain infection, and (3) host-pathogen interactions, including how HIV-driven immune dysfunction changes bacterial behavior and the trajectory from latent to active TB.
6) What does the opportunity mean by "microbiologic adaptive mechanisms"?
It refers to how the bacterium adapts under immune pressure and constrained conditions such as low nutrient availability, low oxygen, or other limiting environments that may occur during latent infection.
7) What does the opportunity mean by "host immunologic factors"?
It refers to immune cell types, signaling pathways, inflammatory environments, and protective responses that help contain Mycobacterium tuberculosis and keep infection in a latent (controlled) state.
8) What kinds of host-pathogen interaction questions are considered relevant?
Relevant questions include how bacterial adaptations shape immune responses, and how HIV-related immune dysfunction changes those immune responses, alters bacterial behavior, and increases the likelihood of progression from latent infection to active TB disease.
9) Why is HIV co-infection a central focus of this announcement?
Because people living with HIV have a substantially higher risk of progressing from latent TB to active TB, and the biological reasons for this elevated risk are complex and not fully understood.
10) What types of outcomes or insights are responsive to this opportunity?
Projects are expected to clarify mechanisms, markers, or pathways that explain why latency fails more often in HIV co-infection, with potential relevance to improved preventive strategies, diagnostics, vaccines, or host-directed therapies.
11) Does the announcement require cost sharing or matching funds?
No. The opportunity states that no cost sharing or matching is required as a condition of award.
12) What CFDA numbers are associated with this opportunity?
This opportunity is associated with CFDA 93.855 (Allergy and Infectious Diseases Research) and CFDA 93.856 (Microbiology and Infectious Diseases Research).
13) When was PAR-13-061 posted and created?
The opportunity was posted and created on December 20, 2012.
14) What were the closing dates for this opportunity?
The original closing date was July 24, 2015, and the final closing date was also July 24, 2015.
15) Is this opportunity still open for applications?
No. It was archived on August 24, 2015, and the final closing date was July 24, 2015.
16) What types of organizations are eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status, other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and various government entities (including city/township, county, and state governments), special district governments, and independent school districts.
17) Are tribal entities eligible to apply?
Yes. Tribal governments and tribal organizations are explicitly included as eligible applicants.
18) Are public housing authorities eligible?
Yes. Public housing authorities and Indian housing authorities are listed as eligible applicants.
19) Are minority-serving institutions included in the eligible applicant types?
Yes. The eligibility list explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander-Serving Institutions (AANAPISI).
20) Are faith-based or community-based organizations eligible?
Yes. Faith-based and community-based organizations are explicitly included as eligible applicants.
21) Can federal agencies apply?
Yes. Eligible federal agencies may apply.
22) Are foreign (non-U.S.) organizations allowed to apply?
Yes. Non-U.S. entities (foreign organizations and foreign institutions) are eligible to apply.
23) Can a U.S. organization include non-U.S. components in its application?
Yes. Non-U.S. components of U.S. organizations may participate.
24) Are "foreign components" allowed under NIH policy?
Yes. Foreign components (as defined by the NIH Grants Policy Statement) are allowed, enabling overseas performance sites, collaborations, cohorts, or laboratory components when scientifically justified.
25) Why might international participation be important for this topic?
TB and HIV research often depends on patient populations and transmission settings outside the United States, and conducting parts of a study in high-burden settings can be essential for addressing questions about latency and reactivation.
26) What NIH mission areas does this opportunity align with?
It aligns with health-related research in NIH mission space relevant to allergy, immunology, microbiology, and infectious diseases.
27) Where can applicants find the official Funding Opportunity Announcement text?
The full announcement is available at: http://grants.nih.gov/grants/guide/pa-files/PAR-13-061.html
28) Who should be contacted for technical issues accessing or linking to the announcement?
Technical issues can be directed to the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Herat Media Information Center
Previous opportunity: Pain in Aging (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 061
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 061) also looked into and applied for these:
| Funding Opportunity |
|---|
| Integrating Newborn Screening Long term Follow up into Primary Care Practices Apply for HRSA 13 213 Funding Number: HRSA 13 213 Agency: Health Resources and Services Administration Category: Health Funding Amount: $110,000 |
| Limited Competition Initiative to Maximize Research Education in Genomics (R25) Diversity Action Plan Apply for PAR 13 063 Funding Number: PAR 13 063 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Building healthcare practitioner capacity around HPV Vaccine Communication Apply for RFA IP 13 001 Funding Number: RFA IP 13 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Revisions for Macromolecular Interactions in Cells (R01) Apply for RFA GM 14 003 Funding Number: RFA GM 14 003 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Telehealth Resource Center Grant Program Apply for HRSA 13 167 Funding Number: HRSA 13 167 Agency: Health Resources and Services Administration Category: Health Funding Amount: $325,000 |
| Implementation Support for State Demonstrations to Integrate Care for Medicare Medicaid Enrollees Apply for CMS 1I1 13 001 Funding Number: CMS 1I1 13 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $15,000,000 |
| Sober Truth on Preventing Underage Drinking Act Grants Apply for SP 13 001 Funding Number: SP 13 001 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $50,000 |
| The CDCs National Undergraduate Student Program A Public Health Workplace Experience to Increase Student Interest in Public Health Apply for CDC RFA MN11 1101 Funding Number: CDC RFA MN11 1101 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,850,000 |
| FY 2013 Cooperative Agreements for the National Suicide Prevention Lifeline Crisis Center Follow Up Apply for SM 13 002 Funding Number: SM 13 002 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $60,000 |
| Planning Grants for Expansion of the Comprehensive Community Mental Health Services for Children and Their Families Apply for SM 13 001 Funding Number: SM 13 001 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $800,000 |
| Support of Competitive Research (SCORE) Research Advancement Award (SC1) Apply for PAR 13 069 Funding Number: PAR 13 069 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Support of Competitive Research (SCORE) Pilot Project Award (SC2) Apply for PAR 13 070 Funding Number: PAR 13 070 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Support of Competitive Research (SCORE) Research Continuance Award (SC3) Apply for PAR 13 071 Funding Number: PAR 13 071 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| International Research Scientist Development Award (IRSDA) (K01) Apply for PAR 13 072 Funding Number: PAR 13 072 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Clinical Study Planning Grant Program (R34) Apply for PAR 13 073 Funding Number: PAR 13 073 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Functional Epigenomics Developing Tools and Technologies for Cell type, Temporal, or Locus specific Manipulation of the Epigenome (R01) Apply for RFA RM 12 026 Funding Number: RFA RM 12 026 Agency: National Institutes of Health Category: Health Funding Amount: $325,000 |
| Human Immunodeficiency Virus (HIV) Prevention Projects for the Commonwealth of Puerto Rico and United States Virgin Islands Apply for CDC RFA PS13 1310 Funding Number: CDC RFA PS13 1310 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Healthcare Management and Administration (HMA) Education Twinning in Mozambique Apply for RFA 656 13 000006 Funding Number: RFA 656 13 000006 Agency: Mozambique USAID Maputo Category: Health Funding Amount: $2,000,000 |
| Leveraging Existing Natural Experiments to Advance the Health of People with Severe Mental Illness (R24) Apply for RFA MH 13 140 Funding Number: RFA MH 13 140 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Competitive Revision Applications for Research on Complementary Approaches to Symptom Management in Military and Veteran Populations (R01) Apply for PA 13 075 Funding Number: PA 13 075 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 061", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.